Since MAPK pathway reactivation is a common theme of tumor-escape mechanisms with BRAF inhibitors, the combination of a BRAF inhibitor and a MEK inhibitor has been evaluated and shown to generate superior benefit in prolonging progression-free survival and reducing cutaneous adverse events in BRAF inhibitor-naive patients (Long et al., 2014). This evidence concerns the gene MAP2K7 and neoplasm.